



RECEIVED
JAN 03 2001
TECH CENTER 1600/2900
1631

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

ELI LILLY AND COMPANY

By Linda M. Durbin

Date November 20, 2001

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Mark L. Brader, et al.)
Serial No. : 08/484,542)
Filed : June 7, 1995) Group Art Unit:
For : STABILIZED ACYLATED INSULIN) 1631
FORMULATIONS) Examiner:
Docket No. : X-10097) M. Allen

33
Plunkett
1-11-02

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

BEST AVAILABLE COPY

Sir:

Under the guidelines of 37 C.F.R. 1.97, Applicants submit a copy of each of the documents listed on the attached Form PTO-1449 (modified) for consideration by the Examiner. Appplicants request that the Examiner indicate that the listed documents have been considered by initialing each listed document on the Form PTO-1449, and returning a copy of same to the undersigned.

A Request For Continued Examination (RCE) was filed on October 9, 2001. Accordingly, it is believed that no fee is required for the present supplemental information disclosure statement.

In addition to the documents listed on the attached Form PTO-1449, the Examiner's attention is respectfully directed to

the following co-pending applications, and to the materials provided herewith.

(1) U.S. Application No. 09/761,903, filed January 17, 2001, Atty. Docket X-11232A. A copy of the pending claims for the application are provided herewith. The application is a continuing application of U.S. Application No. 09/177,685, which issued as U.S. Patent No. 6,268,335. U.S. 6,268,335 is listed on the Form PTO 1449 filed herewith, and a copy of the patent is provided herewith.

(2) U.S. Application No. 09/530,038, which is the U.S. National Phase of PCT/US98/22313, filed October 22, 1998, entitled "Fatty Acid-Acylated Insulin Analogs," Atty. Docket X-11574. Provided herewith are a copy of the application and a copy of the Preliminary Amendment filed April 24, 2000, containing pending claims 86-124.

(3) U.S. Application No. 09/217,275, filed December 21, 1998, entitled "Insoluble Compositions For Controlling Blood Glucose," Atty. Docket X-11860. A copy of the application is provided herewith. Claims 1-53 are pending in the application.

(4) U.S. Application No. 09/491,253, filed January 26, 2000, entitled "Monodisperse Hexameric Acylated Insulin Analog Formulation," Atty. Docket X-12020. Provided herewith are a copy of the application and a copy of pending claims 1-63.

(5) U.S. Application No. 09/958,536, which is the U.S. National Phase Of International Application No. PCT/US00/08723, filed April 13, 2000, entitled "Insulin Crystals For Pulmonary Administration," Atty. Docket No. X-12709. Provided herewith are a copy of the application, and a copy of the claims as amended upon entry into the U.S. National Phase.

(6) The U.S. National Phase Of International Application No. PCT/US00/15037, filed June 15, 2000, entitled

BEST AVAILABLE COPY

"Protamine-Free Insoluble Acylated Insulin Compositions," Atty. Docket No. X-12785. Provided herewith are a copy of the application, and of the claims as amended upon entry into the U.S. National Phase.

(7) The U.S. National Phase Of International Application No. PCT/US00/15026, filed June 12, 2000, entitled "Insulin Crystals For Pulmonary Administration," Atty. Docket No. X-13134. Provided herewith are a copy of the application, and of the claims as amended upon entry into the U.S. National Phase.

Applicants request consideration of these co-pending applications and the claims therein.

Respectfully submitted,


Grant E. Reed
Attorney for Applicants
Registration No. 41,264
Phone: 317-276-1664

Eli Lilly and Company
Patent Division/GER
Lilly Corporate Center
Indianapolis, IN 46285

11/19/2001

REST AVAILABLE COPY